Circulating tumor DNA (ctDNA) has been discovered to have restricted medical advantages when added to plain beneficial surveillance amongst sufferers with levels 2 to 4 colorectal most cancers who underwent curative-intent surgical procedure, researchers have discovered.
“You are going to miss recurrences for those who do ctDNA alone — that is not adequate,” mentioned Dr. Marwan Fakih of Metropolis of Hope Complete Most cancers Middle in Duarte, California in an interview with CURE®.
Fakih, one of many co-author of the examine printed in JAMA Community Open, is a professor within the Division of Medical Oncology and Therapeutics Analysis, co-directs the Gastrointestinal Most cancers Program and is the Judy and Bernard Briskin Distinguished Director of Scientific Analysis. Fakih mentioned the examine’s findings and their significance for sufferers.
The retrospective examine included information from 184 sufferers handled at Metropolis of Hope Complete Most cancers Middle and have been monitored with a serial ctDNA assay and Nationwide Most cancers Middle Community-guided radiographic imaging surveillance between Sept. 20, 2019 and April 3, 2024, with a median follow-up of 26 months. ctDNA assays have been carried out each three months for 2 years and each six months for the next three years.
ctDNA, based on the Nationwide Most cancers Institute, is made up of small items of DNA launched right into a affected person’s blood by tumor cells, and it may be used as a biomarker to assist diagnose some cancers, assist plan therapy or decide how nicely therapy is working or if most cancers has returned.
Researchers reported that 45 sufferers (24.5%) had ctDNA or imaging-confirmed recurrence, and of these sufferers 14 had radiographic recurrence with adverse ctDNA and 11 had concurrent ctDNA and imaging recurrence, whereas 20 sufferers had ctDNA positivity with negativing imaging at first ctDNA positivity.
Eleven of the 20 sufferers with ctDNA recurrence with out preliminary concurrent imaging recurrence had subsequent mastectomy, and three (1.6%) of the surveilled inhabitants, have been disease-free on the information cutoff in April 2024.
“Should you’re within the [other] 98% of sufferers, you possibly can argue that technique was not useful for these sufferers, and price the well being care system lots of {dollars},” Fakih mentioned.
Fakih mentioned the examine’s findings and their significance for sufferers.
Transcript:
On the finish of the day, we discovered about three instances within the [approximately] 180 sufferers that we adopted that finally had surgical procedure, and the place the surgical procedure up to now had been helpful, and in order that’s why, on the finish of the day we are saying that if you survey these 180-plus sufferers on the finish of the day, 1.6% of the sufferers who have been surveyed by Signatera [ctDNA assay], finally, that led to a healing surgical intervention down the highway.
Now, for those who’re the 1% of sufferers, that’s nice. Should you’re within the [other] 98% of sufferers, you possibly can argue that technique was not useful for these sufferers, and price the well being care system lots of {dollars}. And so these are questions that we now have to ask ourselves as a society as to what’s essential to do and at what value.
I believe the opposite large query, frankly, is that even these three sufferers who finally had surgical procedure, these sufferers would have anyway, even for those who hadn’t completed Signatera, continued to have some type of imaging on an each six months foundation or on a yearly foundation. Ultimately, you in all probability would have discovered these tumors, and finally you in all probability may have resected these tumors and possibly it may have nonetheless have been a healing end result. And so we do not even know that these lower than 2% of sufferers who finally had healing surgical intervention would have actually not have had the identical choice, had they continued with out Signatera.
Now you can argue this the opposite means round, and say, ‘Hey, what if they’d waited for CT imaging, and a 12 months later, and now the most cancers has unfold even additional, and you may’t resect it.’ So these are unknowns.
And so I believe the significance of this examine is that, primary, it confirms what we now have mentioned earlier than. You are going to miss recurrences for those who do ctDNA alone. That is not adequate. After we take a look at the sufferers who had recurrence by CT and the ctDNA was adverse, there was a better proportion of these sufferers who really had a healing surgical intervention. So CT imaging is customary of care and continues [to be so].
Transcript has been edited for readability and conciseness.
For extra information on most cancers updates, analysis and schooling, don’t overlook to subscribe to CURE®’s newsletters right here.
